Literature DB >> 28265599

Screening methods for identifying pharmacological chaperones.

Min Hyeon Shin1, Hyun-Suk Lim1.   

Abstract

Protein folding is crucial for most proteins to achieve their correct three-dimensional conformations and function properly. Defects in protein folding frequently caused by mutations lead to a range of protein misfolding diseases, including Alzheimer's disease, Parkinson's disease, cystic fibrosis, amyloidosis, Gaucher disease, etc. One approach to treat these devastating diseases would be to use pharmacological chaperones, which are small-molecules that bind to and stabilize misfolded proteins, thereby correcting their pathogenic misfolding and rescuing their functions. As such, pharmacological chaperone therapy holds great promise for the treatment of numerous protein misfolding diseases. In this review, we highlight recent strategies for identifying small-molecules that act as pharmacological chaperones and revert protein misfolding diseases, with a focus on reports within the last five years.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28265599     DOI: 10.1039/c6mb00866f

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  8 in total

1.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

2.  E-Learning for Rare Diseases: An Example Using Fabry Disease.

Authors:  Chiara Cimmaruta; Ludovica Liguori; Maria Monticelli; Giuseppina Andreotti; Valentina Citro
Journal:  Int J Mol Sci       Date:  2017-09-24       Impact factor: 5.923

Review 3.  Second-Generation Pharmacological Chaperones: Beyond Inhibitors.

Authors:  My Lan Tran; Yves Génisson; Stéphanie Ballereau; Cécile Dehoux
Journal:  Molecules       Date:  2020-07-09       Impact factor: 4.411

4.  Mechanism of Action of VP1-001 in cryAB(R120G)-Associated and Age-Related Cataracts.

Authors:  Kathleen S Molnar; Bryan M Dunyak; Bonnie Su; Yevgeniy Izrayelit; Brittney McGlasson-Naumann; Paul D Hamilton; Mingxing Qian; Douglas F Covey; Jason E Gestwicki; Leah N Makley; Usha P Andley
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-08-01       Impact factor: 4.799

Review 5.  Succinic Semialdehyde Dehydrogenase Deficiency: An Update.

Authors:  Miroslava Didiášová; Antje Banning; Heiko Brennenstuhl; Sabine Jung-Klawitter; Claudio Cinquemani; Thomas Opladen; Ritva Tikkanen
Journal:  Cells       Date:  2020-02-19       Impact factor: 6.600

Review 6.  Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.

Authors:  Ludovica Liguori; Maria Monticelli; Mariateresa Allocca; Bruno Hay Mele; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

Review 7.  Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.

Authors:  Juan Camilo Losada Díaz; Jacobo Cepeda Del Castillo; Edwin Alexander Rodriguez-López; Carlos J Alméciga-Díaz
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923

8.  Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and C-5a-Substituted Derivatives of 4-epi-Isofagomine.

Authors:  Patrick Weber; Martin Thonhofer; Summer Averill; Gideon J Davies; Andres Gonzalez Santana; Philipp Müller; Seyed A Nasseri; Wendy A Offen; Bettina M Pabst; Eduard Paschke; Michael Schalli; Ana Torvisco; Marion Tschernutter; Christina Tysoe; Werner Windischhofer; Stephen G Withers; Andreas Wolfsgruber; Tanja M Wrodnigg; Arnold E Stütz
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.